MitraClip™ is the first minimally invasive TEER* therapy that delivers a life-changing treatment option for select patients with primary or secondary mitral regurgitation who would otherwise go untreated.1,2 MitraClip is the standard of care in TMVr built on the only proven mitral valve therapy with over 18 years of experience, an extensive body of clinical evidence, and more than 150K patients treated worldwide.3
*TEER is also referred to TMVr (Transcatheter Mitral Valve Repair)
Built to Repair. Proven to Restore.
MitraClip delivers uncompromising performance in TEER and sets the standard in clinical outcomes. With each generation of MitraClip, Abbott remains at the forefront of therapeutic expertise, partnering with heart teams to help select patients with MR reclaim their lives.
PATIENTS WHO BENEFIT
A better quality of life is possible for your patients with MR
MitraClip™ transcatheter edge-to-edge repair (TEER) is a minimally invasive treatment option for select patients with:
- Significant Primary MR patients who are at a prohibitive surgical risk
- Significant secondary MR patients who remain symptomatic despite maximally tolerated GDMT
“Scott is a lifelong athlete who found himself on the sidelines with significant mitral regurgitation. Learn about his experience receiving MitraClip therapy and his journey back to an active lifestyle.”
This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.
The catalyst for a significant evolution in MR guidelines
Transcatheter edge-to-edge repair (TEER) therapy is now recommended by both the 2022 AHA/ACC/HFSA Guideline4 and the 2020 ACC/AHA Guideline5 for select primary and secondary* MR patients. Determining the severity of MR is an important factor in the management of the condition. The guidelines4,5 support aggressive monitoring and early action, with the goal of preventing complications due to LV volume overload.4
MitraClip is the only US-approved TEER, serving as the foundation for TEER recommendations for both primary MR and secondary MR.4
*Severely symptomatic SMR patients despite optimal GDMT.
- Surgical intervention not offered or denied
49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.5 If left untreated, MR initiates a cascade of events leading to death, with 1-year mortality up to 57%6
Tailored. Optimized. Proven.
MitraClip TEER system’s dedicated design for the mitral anatomy optimizes navigation for consistent clinical results. Its proven performance and tailored treatment options allow it to treat the broadest range of mitral anatomies.
- Broad range of sizes for tailored treatment8,9
MitraClip G4 offers 4 Clip sizes to help tailor repair based on patient mitral valve anatomy.
- G4 NT is the original MitraClip NT/NTR Clip size
- G4 XT is the equivalent of XTR, with Clip arms that are 3 mm longer than G4 NT and allow for easier grasping due to better reach**
The G4 NTW and XTW clips have a 50% wider grasping area than the NT and XT clips respectively. They are designed to reduce MR with the implantation of a single clip.**
- Treat more patients with more options9-11
MitraClip successfully treats a broad range of valve anatomies in real world use9-11
Nearly 1 in 5 patients treated have valve anatomies considered complex9
Valve anatomies include: presence of severely degenerative leaflets, wide flail gaps or widths, calcified landing zone, wide jet, primary jet outside of A2/P2, and more.9
"Long arm clip use was associated with improved MR reduction for severe baseline MR, smaller annular dimensions, larger prolapse gaps and complex mitral valve anatomy in primary MR."
– Cardiac Surgeon with over 10 years of experience with MitraClip*
*The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.
CLIP SELECTION CONSIDERATIONS
Leaflet Length < 9mm + + Leaflet Length ≥ 9mm + + Broad Jet + + Smaller Valve + Larger Valve + + +
MitraClip G4 clip selection recommendations were based on the initial clinical experience of an expert panel of physicians.9,10
FOR PATIENTS WITH PMR
XTW was used most often and achieved favorable MR reduction, particularly in patients with longer leaflets, large prolapse or wider jets, calcified leaflets or annulus and Barlow’s or bileaflet prolapse
FOR PATIENTS WITH SMR
NTW and XTW were used most often, evenly across anatomies and achieved favorable MR reduction
FOR ALL MR ETIOLOGIES
XT and XT were used more frequently in multiple-clip cases and improved MR reduction
- More options to confirm and optimize leaflet grasping with Controlled Gripper Actuation (CGA)1,3
Controlled Gripper Actuation (CGA) provides the option to grasp leaflets simultaneously or independently, enabling the ability to confirm and optimize leaflet grasp.
- Predictable procedure experience8
The innovative Clip Delivery System is a highly maneuverable delivery catheter that is used to implant the MitraClip via a Steerable Guide Catheter.
Precision and stability from delivery system specifically designed for the mitral valve**
- Increased procedural efficiency1,10
OF PATIENTS TREATED
WITH 1 CLIP10
1 CLIP IMPLANTED IN
65% OF CASES10
34 MIN. MEDIAN
“IN OUR INSTITUTE, WE HAVE NOW REDUCED DEVICE TIME TO ~20 MIN.”
Echocardiographer with 6 years of MitraClip experience, commenting on MitraClip G4*
Simplified procedural steps1
- 40% reduction in system preparation steps
- Simplified system deployment with minimal number of steps
LEARN MORE ABOUT MITRACLIP G4 FEATURES BY VISITING MITRACLIP.COM
MAT-2010220 v5.0 | Item approved for U.S. use only.